JPS6281315A - Remedy for bacterial dermatosis such as athlete's foot - Google Patents

Remedy for bacterial dermatosis such as athlete's foot

Info

Publication number
JPS6281315A
JPS6281315A JP22031785A JP22031785A JPS6281315A JP S6281315 A JPS6281315 A JP S6281315A JP 22031785 A JP22031785 A JP 22031785A JP 22031785 A JP22031785 A JP 22031785A JP S6281315 A JPS6281315 A JP S6281315A
Authority
JP
Japan
Prior art keywords
group
compound
remedy
skin
foot
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP22031785A
Other languages
Japanese (ja)
Other versions
JPH0751506B2 (en
Inventor
Takao Iwasaki
岩崎 孝男
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to JP22031785A priority Critical patent/JPH0751506B2/en
Publication of JPS6281315A publication Critical patent/JPS6281315A/en
Publication of JPH0751506B2 publication Critical patent/JPH0751506B2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Landscapes

  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

PURPOSE:To provide the titled remedy containing a specific compound as active component having vitamin B1 activity, penetrable deep into the skin, decomposable in the body to form a strong microbicidal substance and free from side effect such as skin irritation, development of red spot, etc. CONSTITUTION:The compound of formula (R1 is methyl, ethyl, propyl, etc.; R2 is methyl, ethyl, allyl, etc.), its hydrochloride or nitrate is used as a remedy for bacterial dermatosis such as athlete's foot. The compound of formula is decomposed into thiamine and an alkyl sulfide in the body to exhibit strong microbicidal effect and imparts strong effect against the microorganism living in the deep part of the skin. The compound of formula is an epoch-making remedy having chemical stability, free from side effect such as skin irritation or development of red spot and acting as a useful vitamin B1 when absorbed in the body.

Description

【発明の詳細な説明】 水虫等の細菌性皮膚病は細菌か皮膚の深部に生そくする
為に、根治する事が非常に困難であり、決定的な治療薬
のないのが現状である。本発明者は長年研究の結果画期
的な効果を有する治療薬の011発に成功した。
DETAILED DESCRIPTION OF THE INVENTION Bacterial skin diseases such as athlete's foot are extremely difficult to cure because bacteria grow deep within the skin, and there is currently no definitive treatment. As a result of many years of research, the inventor of the present invention has succeeded in developing a therapeutic drug 011 that has an epoch-making effect.

本発明に依る治療薬は次の一般式で表わされる。The therapeutic agent according to the present invention is represented by the following general formula.

し ここてR+はメチル基、エチル基、プロピル基てR2は
メチル基、エチル基、プロピル基、アリルフルフリルU
てあイ、31本化合物はビタミン81作用物質であり、
そのままでは余り殺菌力はないが、作用機構としては皮
膚によく吸収され体内に於て分解されチアミンとアルキ
ルサルファイドを生成し、強力な殺菌効果を発揮するも
のと思われる。従って本発明に依れば皮膚の17部に迄
よく浸透して深部の細菌に強力な作用を及はすと考えら
れる。本化合物は化Y的に安定であり、皮膚に2.I 
してJ!11激発赤等の害は全くなく、しかも吸収され
ても毒性かないどころか、イj″用なビタミ/B1とし
て作用する画期的な水虫等の治療薬である。
Here, R+ is a methyl group, ethyl group, propyl group, and R2 is a methyl group, ethyl group, propyl group, allylfurfuryl U.
Yes, this compound is a vitamin 81 active substance,
Although it does not have much bactericidal power as it is, its mechanism of action is that it is well absorbed into the skin and decomposed in the body to produce thiamine and alkyl sulfide, which is thought to exert a strong bactericidal effect. Therefore, according to the present invention, it is thought that it can penetrate well into 17 parts of the skin and exert a strong effect on bacteria deep inside. This compound is chemically stable and has 2. I
Do J! 11 does not cause any harmful effects such as severe redness, is not toxic even if absorbed, and is an innovative treatment for athlete's foot, etc., which acts as a vitamin/B1 for IJ''.

治療効果等の詳細は実施例によ−〕で説明する。Details of therapeutic effects and the like will be explained in Examples.

実施例=1 本文中の一般式てR1がメチル基、R2かエチル基の化
合物チアミ/エチルジサ゛レフアイドア1部を親水ワセ
リン(局方)によく混練して治療薬とした。これを男な
各5人の右足の四部に1g塗布した。同程度水虫におか
された左足は親水ワセリ719を塗布した。本発明の治
療薬を塗布した右足は三回の塗布で1人が全治し、賎る
3人もミロの塗布で全治した。親水ワセリンだけの左足
はミロの塗布に依っても何ら効果はなかった。又同時に
左腕上はく部に塗布してバッチテストを行ったが全員発
赤その他異常は全く見られなかった。尚2回目以後の塗
布は24時間ごとに行い塗布後24時間で判定した。
Example = 1 One part of thiami/ethyl disarefider, a compound of the general formula in which R1 is a methyl group and R2 is an ethyl group, was thoroughly kneaded with hydrophilic petrolatum (pharmacopoeia) to prepare a therapeutic agent. 1 g of this was applied to the four parts of the right foot of each of five male subjects. Hydrophilic petrolatum 719 was applied to the left foot, which was affected by athlete's foot to the same extent. One patient's right leg was completely cured after applying the therapeutic agent of the present invention three times, and three patients were completely cured after applying Milo. The left foot, which was only treated with hydrophilic Vaseline, had no effect even after applying Milo. At the same time, a batch test was conducted by applying it to the upper calf of the left arm, but no redness or other abnormalities were observed in any of the patients. The second and subsequent applications were carried out every 24 hours, and judgment was made 24 hours after application.

実施例−2 R1がエチル基、R2がプロピル基の化合物を実施例−
1と同様に処理して同し試験を行った結果略同様の結果
が得られた。
Example 2 Example of a compound in which R1 is an ethyl group and R2 is a propyl group
The same test was conducted in the same manner as in No. 1, and almost the same results were obtained.

実施例−3 R1がメチル基、 R2がアリル基の化合物を実施例−
2と同様の処理をして試験した結果、略同様の結果が得
られた。
Example 3 Example of a compound in which R1 is a methyl group and R2 is an allyl group
As a result of testing with the same treatment as 2, substantially the same results were obtained.

実施例−4 実施例−3と同し化合物を05部、親水ワセリ/995
部を実施例−1と同(・贅に処理して試験した結果2回
の塗布で4人、3回で6人と全員完治した。
Example-4 05 parts of the same compound as Example-3, hydrophilic petrolatum/995
The skin was treated in the same way as in Example 1 (*) and as a result of the test, 4 people were completely cured after applying it twice, and 6 people after applying it 3 times.

Claims (1)

【特許請求の範囲】 次の一般式で表わされる化合物を有効成分とする、水虫
等細菌性皮膚病の治療薬▲数式、化学式、表等がありま
す▼ ここでR_1はメチル基、エチル基、プロピル基、ブチ
ル基、R_2はメチル基、エチル基、プロピル基、アリ
ル基、フルフリル基を表わす。又本化合物の塩酸塩硝酸
塩も含まれる。
[Claims] A therapeutic agent for bacterial skin diseases such as athlete's foot containing a compound represented by the following general formula as an active ingredient ▲ There are mathematical formulas, chemical formulas, tables, etc. ▼ Here, R_1 is a methyl group, an ethyl group, a propyl group. group, butyl group, R_2 represents a methyl group, ethyl group, propyl group, allyl group, or furfuryl group. Also included are hydrochloride and nitrate salts of the present compound.
JP22031785A 1985-10-04 1985-10-04 Remedy for bacterial skin diseases such as athlete's foot Expired - Lifetime JPH0751506B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP22031785A JPH0751506B2 (en) 1985-10-04 1985-10-04 Remedy for bacterial skin diseases such as athlete's foot

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP22031785A JPH0751506B2 (en) 1985-10-04 1985-10-04 Remedy for bacterial skin diseases such as athlete's foot

Publications (2)

Publication Number Publication Date
JPS6281315A true JPS6281315A (en) 1987-04-14
JPH0751506B2 JPH0751506B2 (en) 1995-06-05

Family

ID=16749245

Family Applications (1)

Application Number Title Priority Date Filing Date
JP22031785A Expired - Lifetime JPH0751506B2 (en) 1985-10-04 1985-10-04 Remedy for bacterial skin diseases such as athlete's foot

Country Status (1)

Country Link
JP (1) JPH0751506B2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0614886A1 (en) * 1992-07-30 1994-09-14 Drug Delivery System Institute, Ltd. Compound capable of intracerebral residence and use thereof
WO1995020388A1 (en) * 1994-01-26 1995-08-03 Nissui Pharmaceutical Co., Ltd. Anti-hiv drugs

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0614886A1 (en) * 1992-07-30 1994-09-14 Drug Delivery System Institute, Ltd. Compound capable of intracerebral residence and use thereof
EP0614886A4 (en) * 1992-07-30 1994-10-12 Drug Delivery System Inst Ltd Compound capable of intracerebral residence and use thereof.
WO1995020388A1 (en) * 1994-01-26 1995-08-03 Nissui Pharmaceutical Co., Ltd. Anti-hiv drugs

Also Published As

Publication number Publication date
JPH0751506B2 (en) 1995-06-05

Similar Documents

Publication Publication Date Title
RU2477136C2 (en) Alkaloid formulations
US4424232A (en) Treatment of herpes simplex
US4321257A (en) Potentiated medicaments
ATE16191T1 (en) STABLE SALTS OF S-ADENOSINYLMETHIONINE, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE DERIVATIVES AS THE ACTIVE SUBSTANCE.
KR880000091A (en) Topical Pharmaceutical Compositions Method of Preparation and Use thereof
JPS63139136A (en) Enhancer for transdermal transmission of general medicine
BR9813373A (en) Compound, process for preparing it, pharmaceutical composition, process for preparing it, use of a compound, and, processes for effecting immunosuppression and for treating or reducing the risk of reversibly obstructive airway disease in a patient
JPS63139137A (en) Permeation accelerator for general medicine transdermal administration
DE60135108D1 (en) DERIVATIVE COMPOSITIONS CONTAINING AS ACTIVE COENZYME Q.
US4107331A (en) Zinc chelating fungicidal composition
US2761807A (en) Glycocyamine and methylating agent in vivo creatine producing composition
JPS6281315A (en) Remedy for bacterial dermatosis such as athlete's foot
BR9915962A (en) Pyridinium Series Compound, processes for the preparation of Pyridinium Series Compound and a parenteral formulation, use of a compound, pharmaceutical composition to treat diabetic complications and aging-related diseases, and, method for treating a diabetic patient and preventing or treat diseases caused by complications associated with diabetes and aging
KR910018348A (en) Sulfonylamino substituted bicyclo cyclic hydroxamic acid derivative
DE3344086C2 (en)
US6110971A (en) Fungicide composition comprising a benzoylphenylurea
Jacobs Treatment of fungal skin infections: state of the art
SULZBERGER et al. DEVELOPMENT AND USE OF BAL: A Review, with Particular Reference to Arsenical Dermatitis
DE2806866B2 (en) Use of salts of dithiodialkane sulfonic acids
JPH03120230A (en) Percutaneous absorbefacient of drug active ingredient and percutaneous absorption type pharmaceutical
BR9810214A (en) Compound, pharmaceutical composition, use of a compound, and, processes to treat or reduce the risk of diseases or human conditions, to treat or reduce the risk of inflammatory disease and pain in a person suffering from or at risk of said disease, of treatment, and for the preparation of a compound
DE2221281C3 (en) Pharmaceutical preparations with anti-inflammatory and analgesic effects
JPH07502518A (en) wound disinfectant
BRPI0411536A (en) compounds, pharmaceutical formulation, method for treating or preventing lipid disorders (dyslipidemia) associated or not with insulin resistance, use of compound, method for treating or preventing type 2 diabetes, pharmaceutical composition, and process for preparing a compound
RU2188005C2 (en) Composition for antiseptic treatment of hand skin and operation field